This site is intended for healthcare professionals
Abstract digital waveforms in blue and purple
FDA Drug information

Chlorpromazine Hydrochloride

Read time: 1 mins
Marketing start date: 19 Feb 2025

Summary of product characteristics


Effective Time

20240314

Version

1

Spl Product Data Elements

Chlorpromazine Hydrochloride Chlorpromazine Hydrochloride CHLORPROMAZINE HYDROCHLORIDE CHLORPROMAZINE ASCORBIC ACID SODIUM METABISULFITE SODIUM SULFITE SODIUM CHLORIDE WATER Chlorpromazine Hydrochloride Chlorpromazine Hydrochloride CHLORPROMAZINE HYDROCHLORIDE CHLORPROMAZINE ASCORBIC ACID SODIUM METABISULFITE SODIUM SULFITE SODIUM CHLORIDE WATER

Application Number

ANDA217275

Brand Name

Chlorpromazine Hydrochloride

Generic Name

Chlorpromazine Hydrochloride

Product Ndc

70771-1779

Product Type

HUMAN PRESCRIPTION DRUG

Route

INTRAMUSCULAR

Package Label Principal Display Panel

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL NDC 70771-1778-1 chlorproMAZINE Hydrochloride Injection, USP 25 mg/mL For Deep Intramuscular Use Discard unused portion 1 mL Single-Dose Vial Rx only NDC 70771-1778-7 chlorproMAZINE Hydrochloride Injection, USP 25 mg/mL For Deep Intramuscular Use Discard unused portion 25 x 1 mL Single-Dose Vial Rx only 25 mg/ml 25mg/ml

Spl Unclassified Section

SPL UNCLASSIFIED

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Disclaimer

The drug Prescribing Information (PI), including indications, contra-indications, interactions, etc, has been developed using the U.S. Food & Drug Administration (FDA) as a source (www.fda.gov).

Medthority offers the whole library of PI documents from the FDA. Medthority will not be held liable for explicit or implicit errors, or missing data.

Drugs appearing in this section are approved by the FDA. For regions outside of the United States, this content is for informational purposes only and may not be aligned with local regulatory approvals or guidance.